Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2011

View Archived Issues

Photocross-linked biosynthetic implants provide new tool for soft tissue reconstruction

Scientists genetically engineer E. coli to detect and kill P. aeruginosa

Human monoclonal antibody neutralizes influenza A group 2 viruses

Ranbaxy discloses new DPP IV/ACE inhibitors

New antitumor agents synthesized by Kyowa Hakko Kirin

Vertex discloses new inhibitors of PKC-theta

Novel antitumor agents disclosed by Chinese and U.S. team

New vitamin D analogues claimed

Cynapsus provides update on proposed acquisition of Adagio Pharmaceuticals

Afexa Life Sciences reports on LIP-01 trial in cholesterol management

Adamas Pharmaceuticals begins phase II/III study of ADS-5102

Shionogi advances acquisition of C&O Pharmaceutical Technology

Endo Pharmaceuticals terminates collaboration with Gruenenthal

FDA grants fast track status to DARA's KRN-5500

Kinex Pharmaceuticals begins phase I trial of KX2-391 in AML

Curis doses first patient in CUDC-101 head and neck cancer study

MAA accepted and NDA submitted for ridaforolimus

Hydrogen sulfide replacement may protect against complications of diabetes

Phase II trial of Cell Therapeutics' Opaxio opens enrollment

Furiex closes loan agreement to support development of clinical-stage products

NPS Pharmaceuticals submits CMC section of Gattex NDA to FDA

Antigen Express presents phase II data on anticancer vaccine AE-37 in breast cancer

FDA clears IND to conduct clinical studies of lasmiditan

FDA approves Marshall Edwards' IND for lead NADH oxidase inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...